Editorial: Chronic Liver Disease: New Targets and New Mechanisms, Volume II.
作者信息
Jerez Sofia, Gao Jinhang, Kostallari Enis
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, China.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
出版信息
Front Mol Biosci. 2023 Jul 18;10:1237824. doi: 10.3389/fmolb.2023.1237824. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Chronic Liver Disease: New Targets and New Mechanisms, Volume II.社论：《慢性肝病：新靶点与新机制》第二卷
Front Mol Biosci. 2023 Jul 18;10:1237824. doi: 10.3389/fmolb.2023.1237824. eCollection 2023.
2
Editorial: Chronic Liver Disease: New Targets and New Mechanisms.社论：慢性肝病：新靶点与新机制
Front Mol Biosci. 2022 Jul 18;9:963630. doi: 10.3389/fmolb.2022.963630. eCollection 2022.
3
Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets.社论：非酒精性脂肪性肝病治疗进展：致病机制与靶点
Front Pharmacol. 2022 Nov 10;13:1072353. doi: 10.3389/fphar.2022.1072353. eCollection 2022.
4
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.《向 NASH 开战：复杂肝脏疾病中的新兴靶点和药物研发》
J Med Chem. 2020 May 28;63(10):5031-5073. doi: 10.1021/acs.jmedchem.9b01701. Epub 2020 Jan 29.
5
Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and J. Ellis.疾病状态依赖性药物-草药相互作用：非酒精性脂肪性肝炎降低了与辛伐他汀共同给药的大鼠肝毒性风险及J. 埃利斯相关情况
Front Pharmacol. 2021 Apr 23;12:622040. doi: 10.3389/fphar.2021.622040. eCollection 2021.
6
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.非酒精性脂肪性肝病的分子靶点及新兴药物治疗干预研究进展
Metabolism. 2022 Jan;126:154925. doi: 10.1016/j.metabol.2021.154925. Epub 2021 Nov 2.
7
Osr1 Regulates Macrophage-mediated Liver Inflammation in Nonalcoholic Fatty Liver Disease Progression.Osr1 调控非酒精性脂肪性肝病进展中巨噬细胞介导的肝炎症。
Cell Mol Gastroenterol Hepatol. 2023;15(5):1117-1133. doi: 10.1016/j.jcmgh.2022.12.010. Epub 2022 Dec 27.
8
New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.新型和新兴的抗纤维化治疗药物在慢性肝脏疾病中进入或已经进入临床试验。
Curr Opin Pharmacol. 2019 Dec;49:60-70. doi: 10.1016/j.coph.2019.09.006. Epub 2019 Oct 5.
9
Caveolin-1 Alleviates Acetaminophen-Induced Hepatotoxicity in Alcoholic Fatty Liver Disease by Regulating the Ang II/EGFR/ERK Axis.窖蛋白-1 通过调控血管紧张素 II/表皮生长因子受体/细胞外信号调节激酶轴减轻酒精性脂肪肝疾病中对乙酰氨基酚诱导的肝毒性。
Int J Mol Sci. 2022 Jul 8;23(14):7587. doi: 10.3390/ijms23147587.
10
Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy.异丙叉基苍术苷元通过法尼醇 X 受体激活和 TFEB 介导线粒体自噬发挥多种抗非酒精性脂肪性肝炎（NASH）作用。
Phytomedicine. 2022 Jul 20;102:154148. doi: 10.1016/j.phymed.2022.154148. Epub 2022 May 4.
本文引用的文献
1
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.NASH 的抗炎和抗纤维化治疗靶点的综合观点。
J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14.
2
STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome.STING 通过表观遗传激活 NLRP3 炎性小体介导肝纤维化中的肝细胞细胞焦亡。
Redox Biol. 2023 Jun;62:102691. doi: 10.1016/j.redox.2023.102691. Epub 2023 Mar 29.
3
Global burden of liver disease: 2023 update.全球肝病负担：2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
4
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
5
The evolving role of liver sinusoidal endothelial cells in liver health and disease.肝窦内皮细胞在肝脏健康和疾病中的作用演变。
Hepatology. 2023 Aug 1;78(2):649-669. doi: 10.1097/HEP.0000000000000207. Epub 2023 Jan 3.
6
Mortality in the United States, 2021.2021年美国的死亡率
NCHS Data Brief. 2022 Dec(456):1-8.
7
Mitochondrial alterations in fatty liver diseases.脂肪性肝病中的线粒体改变
J Hepatol. 2023 Feb;78(2):415-429. doi: 10.1016/j.jhep.2022.09.020. Epub 2022 Oct 7.
8
Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.机械转导诱导的糖酵解通过表观遗传调控肝窦内皮细胞中 CXCL1 优势的血管分泌信号通路，在体外和体内研究中。
J Hepatol. 2022 Sep;77(3):723-734. doi: 10.1016/j.jhep.2022.03.029. Epub 2022 Apr 12.
9
Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis.硬度与肝纤维化过程中的肝星状细胞异质性有关。
Am J Physiol Gastrointest Liver Physiol. 2022 Feb 1;322(2):G234-G246. doi: 10.1152/ajpgi.00254.2021. Epub 2021 Dec 23.
10
Role of extracellular vesicles in liver diseases and their therapeutic potential.细胞外囊泡在肝脏疾病中的作用及其治疗潜力。
Adv Drug Deliv Rev. 2021 Aug;175:113816. doi: 10.1016/j.addr.2021.05.026. Epub 2021 Jun 2.
Zotero 插件